Basal cell carcinoma - Kansera Hucreya Bingehîn
☆ AI Dermatology — Free Service
Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Birînên ulcerkirî yên ku bandorê li çermê pozê di kesek pîr de dikin, bi gelemperî wekî Kansera Hucreya Bingehîn (Basal cell carcinoma) têne teşhîs kirin. Poz, ji bo vê celebê kansera çermê, cîhek hevpar e.
Kansera Hucreya Bingehîn (Basal cell carcinoma) dibe ku bi sînorên nerêkûpêk û ulseran re xuya dibe.
Kansera Hucreya Bingehîn (Basal cell carcinoma) dikare ji wartê şaş bibe.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) cureyê herî berbelav a kansera çerm e. Rabûna tîrêja rojê sedema sereke ye. Hema hemû bûyerên BCC di analîza molekular de nîşana Hedgehog‑a zêde aktîf nîşan didin. Dermanên cihêreng hene û li ser bingeha xetera dûbarebûnê, girîngiya parastina tevnevîsê, tercîha nexweş, û asta nexweşiyê têne hilbijartin.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas celeba herî gelemperî ya penceşêra çermê ne, ku di mezinên çermê xweşik ên 50 salî û jor de dîtin. Hejmara wan li çaraliyê cîhanê zêde dibe, bi taybetî ji ber ronahiya rojê. Hin şert û mercên genetîkî dikarin mirovan bikaribin ku di temenek piçûk de van penceşêrê pêşve bibin. Basal cell carcinomas di giraniyê de diguhezin, ji birînên rûpî an nodular ku bi hêsanî têne derman kirin heta yên berfirehtir ên ku hewceyê nîqaşê di tîmên bijîjkî yên pispor de ne. Pêşniyaz bi îhtîmala vegerandina penceşêrê an jî kapasîteya wê ya zirarê bide tevna nêzîk ve girêdayî ye. Neştergerî ji bo pir rewşan dermankirina standard e, ku rakirina rast û kêm şansên dubarebûnê dike. Rêbazên kêmtir dagirker dikarin bi bandor birînên rûvî derman bikin.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Tedawiya bingehîn a BCC, emeliyat e. Ji bo BCC‑ya xeternak an dubarekirî, bi taybetî li deverên krîtîk, emeliyata mîkrografîkî ya kontrolkirî tê pêşniyar kirin. Nexweşên ku BCC‑ya rûkalî ya kêm‑rîsk hene, dikarin dermankirinên topkî an jî rêbazên hilweşîner bifikirin. Terapiya fotodînamîkî ji bo BCC‑yên nodular ên rûpî û kêm‑rîsk baş dixebite. Ji bo BCC‑ya pêşkeftî an metastatîkî ya herêmî, astengkerên Hedgehog (vismodegib, sonidegib) têne pêşniyar kirin. Ger pêşkeftina nexweşiyê an bêtehemûliya mêtingerên Hedgehog hebe, immunoterapî bi anti‑PD1 antibody (cemiplimab) dikare were hesibandin. Radyoterapî ji bo nexweşên ku nikarin emeliyat bikin, bi taybetî ji bo nexweşên pîr, vebijarkek baş e. Ger emeliyat an radyoterapî ne vebijarkek be, dibe ku elektrokemoterapî were hesibandin.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Faktorên xetereyê yên rûdana ronahiya ultraviyole, terapiya tîrêjê, rûbirûbûna demdirêj a arsenîk û fonksiyona pergala belengaziyê (mînak veguheztina organan) vedihewîne. Bi taybetî di zaroktiyê de ronahiya UV xeter e.
Piştî teşhîskirina bi biopsiyê, dermankirin bi gelemperî bi rakirina neştergerî tê kirin. Heke kansera piçûk be, ev dikare bi derxistina hêsan were birin; ger penceşêr ne piçûk be, bi gelemperî emeliyata Mohs tê pêşniyar kirin.
Karsinoma hucreya bingehîn bi kêmî ve 32% ji hemî penceşêrên cîhanê pêk tê. Ji penceşêrên çerm ên ji bilî melanomayê, sedî 80% kansera hucreya bingehîn in. Li Dewletên Yekbûyî, nêzîkî 35% ji mêrên spî û 25% ji jinên spî di demê jiyana xwe de bi kansera hucreya bingehîn bandor dibin.
○ Nîşanî û dermankirin
#Dermoscopy
#Skin biopsy
#Mohs surgery